E.U. Court Tightens Rules For Protecting Drug Patents
The precedent established by the European Court of Justice sets a new, tougher legal standard for what constitutes active ingredients in a drug, which could cost brand-name drug makers large amounts in lost sales by limiting their ability to seek exclusivity extensions.
The European appeals court inherited the...
Already a subscriber? Click here to login